The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:42 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #59. Spectrum Pharmaceuticals Talon Therapeutics, Inc.

Acquirer: Spectrum Pharmaceuticals (NASDAQ:SPPI)
Acquiree: Talon Therapeutics, Inc. (TLON)
Details: Talon Therapeutics, Inc. (OTCQB:TLON) today announced that a subsidiary of Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) entered into an agreement to purchase approximately 89% of the outstanding shares of Talon (the "Company") directly from the Company's principal stockholders. Spectrum also entered into an agreement with the Company under which the subsidiary of Spectrum will purchase additional shares from the Company that, together with the shares acquired from the Company's principal stockholders, will represent in excess of 90% of the outstanding shares of Talon, and under which Spectrum will acquire the remaining outstanding shares of Company common stock through a "short-form" merger of the subsidiary of Spectrum into the Company. The Company and Spectrum expect that the share purchase and the merger will be completed within one business day.

Spectrum Pharmaceuticals is a biopharma company. Co.'s product portfolio consists of in-development drug products for the treatment of cancer patients. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients (including diffuse large B-cell lymphoma).

SPPI SEC Filing Email Alerts Service

Open the SPPI Page at The Online Investor »

Company Name: 
Spectrum Pharmaceuticals Inc
Stock buyback: 
SPPI buyback
Number of ETFs Holding SPPI: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the SPPI Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Strong Buy (3.60 out of 4)
61st percentile
(ranked higher than approx. 61% of all stocks covered)

Analysts' Target Price:
SPPI Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 59 of 83 Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.